Kush Parmar

Kush M.
Parmar is the founder of Immuneel Therapeutics Pvt Ltd., founded in 2018.
Dr. Parmar was the founder of Cruz Blanca Initiative, Inc., founded in 2000, and served as President.
Dr. Parmar is the founder of Ensoma, Inc., founded in 2019, and serves as Director since 2019.
Dr. Parmar currently serves as Chairman at Entrada Therapeutics, Inc. since 2020, Director at Astellas Gene Therapies, Inc. since 2013, Director at Rallybio LLC, Director at Rallybio Holdings LLC, Director at GlycoEra AG since 2022, Secretary & Director at Precede Biosciences, Inc., Managing Partner at 5AM Venture Management LLC since 2010, Managing Member at 5AM Partners V LLC, Advisor at Grace Science Foundation since 2014, Managing Member at 5AM Opportunities I GP LLC, and Managing Member at 5am Partners Vi LLC.
Former positions include Co-Chief Executive Officer & Director at 5:01 Acquisition Corp., Chairman at Homology Medicines, Inc. from 2015 to 2022, Director at Achaogen, Inc., Director at Arvinas Operations, Inc., Director at Envoy Therapeutics, Inc., Director at Cleave Therapeutics, Inc., Independent Director at Astellas Gene Therapies, Inc. from 2013 to 2018, Independent Director at scPharmaceuticals, Inc. from 2014 to 2018, Director at Pulmatrix, Inc., Independent Director at Arvinas, Inc. from 2013 to 2019, Independent Director at Vor Biopharma, Inc. from 2021 to 2023, Independent Director at Akouos, Inc. from 2017 to 2022, Independent Director at Rallybio Corp.
from 2018 to 2024, Independent Non-Executive Director at Syngene International Ltd. from 2021 to 2026, and Vice President-Strategy & Corporate Development at Novira Therapeutics LLC from 2012 to 2015.
Education includes a doctorate from Harvard University conferred in 2008, a doctorate from Massachusetts Institute of Technology conferred in 2010, an undergraduate degree from Princeton University conferred in 2002, and a doctorate from Harvard Medical School conferred in 2010.